# EnGeneIC

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/engeneic

- Industry: Biotechnology
- Headquarters: Sydney, Australia
- Website: www.engeneic.com
- Total disclosed funding: $11M
- Latest round: Series B (Jan 6, 2015)
- Investors on record: 2

## About

EnGeneIC Ltd. is an Australian biotechnology company focused on the research, development, and manufacturing of innovative targeted anti-cancer therapies utilizing its proprietary EnGeneIC Dream Vector (EDV™) technology.Founded in 2000 and headquartered in Sydney, Australia, EnGeneIC Ltd. specializes in targeted cancer therapies. The company has undergone strategic pivots towards developing its proprietary EDV™ technology for treating cancers expressing the Epidermal Growth Factor Receptor (EGFR). In its funding journey, EnGeneIC raised AUD 13 million in Series B financing in January 2015, led by GRT Capital Partners with participation from Foley Ventures. The total amount raised by the company stands at AUD 13 million, following two funding rounds. The CEO, Jennifer MacDiarmid, has been instrumental in steering the company's vision.EnGeneIC specializes in the research, development, and manufacturing of targeted anti-cancer therapies, focusing on its proprietary EnGeneIC Dream Vector (EDV™) technology. Their core offerings include EGFR-targeted EDV™ nanocells that deliver the super-cytotoxic drug PNU-159682 and EDVs containing immune-stimulating adjuvants. These therapies target patients with advanced solid tumors expressing EGFR, fulfilling critical needs in cancer treatment. Initial clinical evaluations, including a multicenter Phase I/IIa trial at Mater Hospital in Sydney, have been conducted to establish safety and efficacy. EnGeneIC's products are targeted for markets in Australia and the USA, with potential expansions into Asia through strategic partnerships.In 2015, EnGeneIC reported revenue of AUD 41,677.10, with an EBITDA of AUD -6,625,329.30. The company's revenue model is based on strategic partnerships and advancing clinical trials, creating revenue streams through technology transfer and GMP batch manufacturing of EDV™ nanocells. Contracts with research institutions and biopharmaceutical companies underpin the financial framework necessary for supporting clinical progression and scaling production.EnGeneIC plans to leverage its recent Series B financing of AUD 13 million, raised in January 2015, to support its ongoing development of the EDV™ technology and advance clinical trials. The focus is on expanding into new markets, particularly in Asia, by establishing strategic partnerships aimed at enhancing distribution capabilities. Upcoming product launches are expected to align with clinical trial advancements, although specific release dates have not been disclosed. The funds raised will facilitate further research, development, and commercialization efforts for their targeted therapies.

## Funding rounds

- Series B, Jan 6, 2015, $11M — Foley Ventures, GRT Capital Partners

## Investors

- Foley Ventures (https://capitalatlas.ai/funds/foley-ventures) — Series B
- GRT Capital Partners — Series B